直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Matthew J. Luneack
Partner
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4436
matthew.luneack@finnegan.com matthew.luneack@finnegan.com

Matthew J. Luneack

Partner

  • +1 202 408 4436 +1 202 408 4436
  • matthew.luneack@finnegan.com matthew.luneack@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Matthew Luneack focuses on patent litigation before U.S. district courts as well as strategic client counseling. His practice covers a variety of technologies, including pharmaceuticals; biotechnology; chemical products and processes; and sports and fitness equipment.

Matthew is involved in all phases of district court litigation, from the initial pleadings through trial and post-trial. His experience includes developing claim construction, infringement, and validity positions; conducting fact and expert discovery; drafting briefs and motion materials; preparing witnesses; taking and defending depositions; arguing claim construction and evidentiary issues; and examining witnesses at trial. Matthew has particular experience representing pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act.

Matthew's counseling practice includes providing strategic advice through opinions of counsel, patent portfolio development and management, due diligence investigations, and freedom-to-operate analyses. He has been recognized by Best Lawyers as "One to Watch."

Prior to his legal career, Matthew gained experience as a research and development intern for Masco Corporation, studying innovative water-saving plumbing products.

Et Cetera

  • Member, Finnegan's Associate Advisory Committee, 2021-2022.
  • Capital Pro Bono Honor Roll, 2019.
  • Managing editor, Vanderbilt Law Review, 2013-2014.
  • Judicial extern, Honorable Magistrate Judge Mark A. Randon, U.S. District Court, Eastern District of Michigan, Summer 2012.

Experience

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Represented Eli Lilly in patent litigations involving antibody therapies.

1:18-cv-12029, D. Mass., Judge Burroughs

In re Fetzima

Represented Allergan and Pierre Fabre in ANDA litigation in the District of New Jersey against multiple generic drug manufacturers seeking to make a generic version of Fetzima® (levomilnacipran) for the treatment of major depressive disorder.

2:17-cv-10230, D.N.J., Judges Mannion, Salas

Duchesnay Inc. v. Actavis Laboratories FL, Inc. et al.

Represented Duchesnay in ANDA litigation in the District of Delaware against multiple generic drug manufacturers seeking to make a generic version of Bonjesta® (doxylaine succinate and phyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy. 

1:18-cv-01895, D. Del., Judges Andrews, Fallon

Valeant Pharmaceuticals Int’l, Inc. v. Actavis Laboratories FL, Inc.

Represented Bausch Health Companies (f/k/a Valeant), Salix, and Progenics in Hatch-Waxman litigation in the District of New Jersey against concerning ANDA for generic oral versions of Relistor® tablets.

2:16-cv-09038, D.N.J., Judges Chesler, Waldor

Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.

Represented Grünenthal in ANDA litigations in the District of Delaware against multiple generic drug manufacturers seeking to make generic versions of Hysingla® ER.

1:15-cv-00687, D. Del., Judges Dyk, Sleet, Stark

Grünenthal GmbH v. Teva Pharmaceuticals

Represented Grünenthal in ANDA litigations against several defendants relating to abuse-deterrent formulations of OxyContin® and Opana®.

1:12-cv-08060, S.D.N.Y., Judges Griesa, Daniels, Gorenstein

More

Insights

Articles

Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation

Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation

May 1, 2023

Bloomberg Law

Federal Circuit IP Blog

Assignor Estoppel Has “No Place” in IPR Proceedings Assignor Estoppel Has “No Place” in IPR Proceedings

November 27, 2018

Federal Circuit IP Blog

Federal Circuit Cautions Against Omitting Preamble Transition Words in Claim Drafting Federal Circuit Cautions Against Omitting Preamble Transition Words in Claim Drafting

November 16, 2018

Federal Circuit IP Blog

Lack of Reasonable Expectation of Success Prohibits Finding of Interference-in-Fact Lack of Reasonable Expectation of Success Prohibits Finding of Interference-in-Fact

October 4, 2018

Articles

Most-Favored-Licensee Provision Did Not Provide a License to Newly-Acquired Patents or Patents that Did Not Trigger the Provision Most-Favored-Licensee Provision Did Not Provide a License to Newly-Acquired Patents or Patents that Did Not Trigger the Provision

March 7, 2017

LES Insights

Articles

Court Finds an Agreement Not-to-Sue Is a Patent License Despite Language to the Contrary Court Finds an Agreement Not-to-Sue Is a Patent License Despite Language to the Contrary

June 14, 2016

LES Insights
More

News

Award/Ranking

Best Lawyers Recognizes 44 Finnegan Attorneys in its 2026 Edition of The Best Lawyers and Ones to Watch Best Lawyers Recognizes 44 Finnegan Attorneys in its 2026 Edition of The Best Lawyers and Ones to Watch

August 21, 2025

Best Lawyers

Award/Ranking

31 Finnegan Attorneys Recognized by Best Lawyers 31 Finnegan Attorneys Recognized by Best Lawyers

August 15, 2024

Best Lawyers

Press Release

32 Finnegan Attorneys Recognized by Best Lawyers

32 Finnegan Attorneys Recognized by Best Lawyers

August 17, 2023

Best Lawyers

Award/Ranking

54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll

July 21, 2023

Press Release

Finnegan Elects Eight New Partners Finnegan Elects Eight New Partners

January 3, 2023

Press Release

29 Finnegan Attorneys Ranked by Best Lawyers

29 Finnegan Attorneys Ranked by Best Lawyers

August 18, 2022

U.S. News—Best Lawyers
More

Professional Activities

  • Virginia Bar Association
Admissions and Education

Admissions

  • District of Columbia
  • Virginia
  • U.S. District Court, D. Massachusetts
  • U.S. District Court, D. New Jersey
  • U.S. District Court, S.D. New York

Education

Vanderbilt University Law School
J.D., 2014
University of Michigan
B.S.E., Chemical Engineering, magna cum laude, 2011

Matthew's Practices

Diligence, Licensing, and Opinions
Due Diligence
Freedom to Operate Opinions
Opinions and Counseling
Global IP Enforcement, Litigation, and Trials
Branded Hatch-Waxman (ANDA) Litigation and Trials
Patent Litigation and Trials
Pretrial Strategies
Prosecution and Portfolio Management
IP Portfolio Management

Matthew's Industries

Chemicals, Industrials, and Materials
Chemical
Manufacturing
Consumer Goods and Services
Consumer Products
Energy
Oil and Gas
Hospitality, Gaming, and Leisure
Sports, Fitness, and Outdoor Recreation
Life Sciences
Biotechnology
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP